Drug Trial Radar · NCT04747613
Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria
Last checked: Nov 20, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
208
Actual
Start
Jul 27, 2021
Primary completion
Oct 18, 2027
Study completion Oct 18, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, single arm, multicenter, roll-over extension study to characterize long-term safety, tolerability and efficacy of iptacopan and to provide access to iptacopan to patients with PNH who have completed Novartis-sponsored Phase 2 or 3 studies with iptacopan
Conditions
- Paroxysmal Nocturnal Hemoglobinuria
Interventions
IptacopanDrug
Taken orally b.i.d. Dosage supplied: 200 mg Dosage form: hard gelatin capsule Route of administration: oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with adverse eventsTime frame: Up to 74 months
Locations
60 sites in 17 countries. Site status is shown where the registry gives one.
City Of Hope National Med Center
Duarte, California
City Of Hope
Duarte, California
USC Norris Cancer Center
Los Angeles, California
Univ Cali Irvine ALS Neuromuscular
Orange, California
Univ of California Irvine (Chao Family Comprehensive Cancer Center)
Orange, California
Lakes Research
Miami Lakes, Florida
Augusta University Georgia
Augusta, Georgia
Augusta University
Augusta, Georgia
Montefiore Medical Center
The Bronx, New York
Cleveland Clinic Foundation
Cleveland, Ohio
Prisma Health Upstate
Greenville, South Carolina
Novartis Investigative Site
Santo André, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Tianjin, China
Novartis Investigative Site
Tianjin, China
Novartis Investigative Site
Brno, Czechia
Novartis Investigative Site
Ostrava, Poruba, Czechia
Novartis Investigative Site
Lille, France
Novartis Investigative Site
Nantes, France
Novartis Investigative Site
Nice, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Toulouse, France
Novartis Investigative Site
Aachen, Germany
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Riesa, Germany
Novartis Investigative Site
Ulm, Germany
Novartis Investigative Site
Dresden, Saxony, Germany
Novartis Investigative Site
Ascoli Piceno, AP, Italy
Novartis Investigative Site
Avellino, AV, Italy
Novartis Investigative Site
Florence, FI, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Torino, TO, Italy
Novartis Investigative Site
Bassano del Grappa, VI, Italy
Novartis Investigative Site
Fukushima, Japan
Novartis Investigative Site
Ishikawa, Japan
Novartis Investigative Site
Kyoto, Japan
Novartis Investigative Site
Niigata, Japan
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.